HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Related Keywords

San Antonio ,Texas ,United States ,Saraa Hurvitz ,Trastuzumab Emtansine , ,Primary Analysis ,Double Blind Phase ,Previously Treated ,Metastatic Breast ,Partnership With ,Antonio Breast Cancer Symposium ,Breast Cancer ,Her2 Metastatic Breast Cancer ,Her2 Positive Metastatic Breast Cancer ,Her2 Breast Cancer ,Ther2 ,Her2 Positive Breast Cancer ,Her2climb 02 ,Tucatinib ,Sabcs ,Clinical Implications ,